Persistence of antimuscarinic drug use

Brostrøm, Søren; Hallas, Jesper

doi:10.1007/s00228-008-0600-9

Cited by 97 publications

(67 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antimuscarinic agents are known to have poor rates of persistence due to bothersome AEs and/ or lack of efficacy [Shaya et al 2005;D'Souza et al 2008;Wagg et al 2012], with discontinuation rates as high as 50% and 75% after 6 months and 1 year, respectively [Brostrom and Hallas, 2009;Benner et al 2010]. Identifying an agent with the optimum balance of efficacy and tolerability remains a major challenge in the management of OAB.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

Batista

Kölbl

Herschorn

et al. 2015

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Objective: To compare the efficacy and safety of mirabegron 50 mg and solifenacin 5 mg in overactive bladder (OAB) patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy. Patients and methods: This randomized, double-blind, phase IIIb, noninferiority study, enrolled male and female patients aged ⩾18 years old, with symptoms of OAB for ⩾3 months, who were dissatisfied with their previous antimuscarinic drug due to lack of efficacy. A total of 1887 patients were randomized to receive mirabegron 50 mg (n = 943) or solifenacin 5 mg (n = 944) daily for 12 weeks. The primary efficacy endpoint was change from baseline to end of treatment in mean number of micturitions/24 h. Noninferiority was confirmed if the lower limit of the two-sided 95% confidence interval (CI) for the treatment difference between solifenacin and mirabegron was > −0.20. Secondary efficacy endpoints, which included change from baseline in mean number of incontinence episodes/24 h, urgency incontinence episodes/24 h, urgency episodes (grade 3 or 4)/24 h and nocturia episodes/24 h, were analyzed using analysis of covariance. Results: For the primary endpoint, adjusted mean treatment difference (95% CI) in mean number of micturitions/24 h was −0.18 (−0.42, 0.06) and therefore noninferiority of mirabegron to solifenacin was not demonstrated. Both treatments demonstrated clinically meaningful reductions in efficacy variables and were well tolerated, with a lower incidence of dry mouth with mirabegron. Conclusions: Noninferiority of mirabegron compared with solifenacin for reduction in micturition frequency could not be demonstrated in this population of OAB patients who were dissatisfied with previous antimuscarinic therapy due to lack of efficacy. Both mirabegron and solifenacin improved key OAB symptoms with no statistically significant differences observed between the two treatments. Both drugs were well tolerated.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

Batista

Kölbl

Herschorn

et al. 2015

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

“…Patients with such condition have the third line treatment options such as bladder augmentation, detrusor myomectomy, or less invasive methods of treatment like botulinum toxin injection to detrusor muscle and electrical stimulation (neuromodulation and neurostimulation). 6,15,16 For intractable OAB, there is a place for appliances, catheters, urethral closure, and urinary diversion. 7 Most OAB patients can take advantages from multimodal therapy consisting of medical therapy, bladder training and pelvic floor muscle training (PFMT).…”

Section: Managementmentioning

confidence: 99%

Management of overactive bladder review: the role of percutaneous tibial nerve stimulation

Wibisono

Rahardjo

2017

Med J Indones

View full text Add to dashboard Cite

ABSTRAK ABSTRACTOveractive bladder (OAB) is a common condition that is experienced by around 455 million people (11% of the world population) and associated with significant impact in patients' quality of life. The first line treatments of OAB are conservative treatment and anti-muscarinic medication. For the refractory OAB patients, the treatment options available are surgical therapy, electrical stimulation, and botulinum toxin injection. Among them, percutaneous tibial nerve stimulation (PTNS) is a minimally invasive option that aims to stimulate sacral nerve plexus, a group of nerve that is responsible for regulation of bladder function. After its approval by food and drug administration (FDA) in 2007, PTNS revealed considerable promise in OAB management. In this review, several non-comparative and comparative studies comparing PTNS with sham procedure, anti-muscarinic therapy, and multimodal therapy combining PTNS and anti-muscarinic had supportive data to this consideration.

show abstract

“…In a recently published study in this journal Broström and Hallas [7] described the outcome of an analysis based on individual-level prescription data from a county in Denmark. The persistence of anticholinergic drug use was calculated based on dispensed products, and Kaplan-Meyer curves were generated for individual substances.…”

Section: Textmentioning

confidence: 99%